 |
| Kidney Cancer Drugs Market |
The kidney cancer drugs market has grown significantly in recent years owing to the rising prevalence of kidney cancer across the globe. Kidney or renal cell carcinoma is one of the most common types of kidney cancers, which starts in the lining of very small tubes (tubules) in the kidneys. Kidney cancer drugs such as targeted therapies and immunotherapy drugs are extensively being used for treatment of renal cell carcinoma. The global kidney cancer drugs market is estimated to be valued at US$ 9.12 billion in 2023 and is expected to exhibit a CAGR of 9.7% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising prevalence of kidney cancer has been a key factor accelerating
growth of the kidney cancer drugs market. According to statistics by the
American Cancer Society, there were over 79,000 new cases of kidney cancer and
over 13,000 deaths from the disease in the United States in 2023. Furthermore,
risk factors such as obesity and hypertension that are increasingly prevalent
have contributed significantly to the high caseload of kidney cancer globally.
Advanced technologies for early screening and diagnosis have also aided in
detecting more kidney cancer cases at early stages, thereby propelling the
demand for effective kidney cancer drugs for treatment. Novel drug formulations
and robust pipeline of targeted therapies in clinical trials continue to expand
treatment options for kidney cancer patients.
Segment
Analysis
The global kidney cancer drugs market is dominated by the renal cell carcinoma
(RCC) segment. Renal cell carcinoma is the most common type of kidney cancer in
adults, accounting for over 90% of kidney cancers. This is because RCC arises
from the lining of the small tubes (tubules) within the kidney that filter
waste from the blood and produce urine. The clear cell type of RCC is the most
common subtype of RCC and is estimated to account for over 70% of all RCC
cases. Due to the high prevalence of clear cell RCC, the drugs used for
treating the clear cell subtype form the dominating segment within the overall
kidney cancer drugs market.
Key Takeaways
The global Kidney
Cancer Drugs Market Share is
expected to witness high growth over the forecast period of 2024-2030.
Regional
analysis: North America is presently the dominant region for the kidney cancer
drugs market. This is attributed to the high incidence of kidney cancer in the
region along with high healthcare spending and presence of established players.
However, the Asia Pacific region is expected to witness the fastest growth over
the forecast period on the back of rising healthcare expenditure, growing
awareness about early detection of cancer, and increasing adoption of advanced
treatment options.
Key players operating in the kidney cancer drugs market are Pfizer Inc.,
Novartis International AG, Exelixis Inc., AstraZeneca plc, Bayer AG, Active
Biotech AB, Amgen Inc., Argos Therapeutics, Bristol-Myers Squibb and Eisai.
For more insights, read- https://www.pressreleasebulletin.com/kidney-cancer-drugs-market-trends-size-and-share-analysis/
Comments
Post a Comment